ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04 مارس 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

04 مارس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

29 فبراير 2024 17:00:33 بحسب Nasdaq GlobeNewswire

Arcutis Announces Pricing of $150 Million Public Offering

28 فبراير 2024 23:30:21 بحسب Nasdaq GlobeNewswire

Arcutis Announces Proposed Public Offering

28 فبراير 2024 16:10:00 بحسب Nasdaq GlobeNewswire

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

28 فبراير 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

27 فبراير 2024 05:50:12 بحسب Nasdaq GlobeNewswire

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

16 فبراير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 فبراير 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference

31 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial

29 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States

22 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

14 يناير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

Majority of Individuals with Atopic Dermatitis Improved with Arcutis’ Roflumilast Cream 0.15% According to New Data from Phase 3 Program

14 يناير 2024 04:00:00 بحسب Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

15 ديسمبر 2023 17:11:43 بحسب Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 ديسمبر 2023 22:00:49 بحسب Nasdaq GlobeNewswire

FDA Accepts Arcutis’ Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

29 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

03 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire